PPD sells rights to inhibitors for $15M up front

PPD has gained a deal to sell its development and marketing rights to all dipeptidyl peptidase IV inhibitors to Takeda for $15 million up front along with unspecified milestones for any successful product development. PPD gained the rights in an earlier deal with Syrrx. Takeda bought Syrrx in March and renamed it Takeda San Diego.

- read this press release for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.